StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) stock

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.77−0.05 (-0.73%)

Close on Nov 16, 2026Market cap $442.67MP/E 42.3Yield –

Arvinas, Inc. saw revenue fall 15.0% to $316.70M over the twelve months to Jun 30, 2026. Free cash flow was -$208.80M. At the latest close the market valued the company at $442.67M, 42.3 times its earnings.

Revenue
$316.70M
-15.0% vs. a year earlier
Operating income
-$18.10M
TTM Q2 2026
Free cash flow
-$208.80M
TTM Q2 2026
EPS, diluted
$0.16
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$442.67M
P/E ratio
42.3
Price to sales
1.40
Price to book
0.79
Dividend yield
–
Free cash flow yield
-47.17%

Fundamentals

Revenue
$316.70M
Net income
$9.30M
EPS, diluted
$0.16
Free cash flow
-$208.80M
Book value per share
$8.56
Diluted shares
66M

Trading

Next earnings
Feb 23, 2027 (estimated, before the open)
Previous close
$6.82
Open
$6.83
Day's range
$6.70 – $6.89
Volume
1,318,402
Average volume (20 days)
956,050
Index membership
Russell 2000, Russell 3000
52-week range
$6.33 – $14.51
RSI (14 days)
41.5
Volatility (1 year)
55.9%
Relative volume
1.62×

On 2 of our idea lists: Net-nets, More cash than they're worth

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2018, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodARVNS&P 500DifferenceARVN per yearS&P 500 per year
1 month-2.9%-3.1%+0.2 pts
3 months-24.5%-4.5%−20.1 pts
Year to date-42.9%+9.4%−52.3 pts
1 year-36.0%+11.3%−47.3 pts
3 years-67.5%+70.4%−137.9 pts-31.2%+19.4%
5 years-91.5%+68.6%−160.1 pts-39.0%+11.0%

Ten years at a glance

Fiscal years 2016 to 2025 and trailing twelve months, USD

Revenue

$316.70M-15.0% YoY

Operating income

-$18.10M

Net income

$9.30M

EPS, diluted

$0.16

Free cash flow

-$208.80M
Reported periodTrailing twelve months

Press releases

Releases Arvinas filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Arvinas

Pharmaceutical Preparations

The company is a clinical-stage biotechnology business that develops targeted therapies using a proprietary proteolysis targeting chimera protein degradation platform. Its technology directs the body's natural protein disposal mechanisms to break down and remove disease-causing proteins. Operating across oncology and neurology therapeutic areas, the company's clinical pipeline includes vepdegestrant for advanced breast cancer, ARV-102 for neurodegenerative disorders, ARV-806 for solid tumors, ARV-393 for non-Hodgkin lymphoma, and ARV-027. The firm also maintains research collaborations with pharmaceutical partners such as Pfizer and Genentech. Its target end-users are patients suffering from severe oncologic and neurological conditions.

Company profile, executives and history

Arvinas stock: common questions

What is Arvinas's stock price?

ARVN closed at $6.77 on Nov 16, 2026, down 0.73% on the day. Over the past 52 weeks it traded between $6.33 and $14.51.

What is Arvinas's market cap?

Arvinas was worth $442.67M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.

What is ARVN's P/E ratio?

ARVN trades at 42.3 times earnings, based on diluted earnings per share of $0.16 over the twelve months to Jun 30, 2026.

How much revenue does Arvinas make?

Arvinas reported revenue of $316.70M for the twelve months to Jun 30, 2026, down 15.0% from a year earlier.

Does Arvinas pay a dividend?

No. Arvinas has not paid a cash dividend over the last twelve months.

When does Arvinas report earnings next?

Arvinas is expected to report Q4 FY2026 results on Feb 23, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has ARVN stock performed over the past year?

Including dividends, ARVN returned -36.0% over the past year, against +11.3% for the S&P 500.

How many ARVN shares are sold short?

6M shares were sold short at the latest FINRA report, 9.54% of the float, or 7.6 days of average trading volume.

Who are Arvinas's competitors?

Companies most similar to Arvinas by business, industry and size include NRIX, ARWR, XNCR, IDYA, FHTX.

See a number that looks wrong?